Will SB 623 Reduce Personal Injury Case Values in California?

California personal injury attorneys have spent the past year watching a piece of proposed legislation with the kind of attention usually reserved for a major appellate decision. SB 623 would change how medical expenses are proven and admitted in personal injury litigation, shifting the baseline from billed charges to a more restrictive standard tied to actual amounts paid or a recognized reasonable-value benchmark. Because medical specials have historically served as a meaningful anchor for calculating both economic and non-economic damages in many California cases, any structural change to how those specials get proven into evidence has the potential to ripple through settlement negotiations, trial verdicts, and ultimately the way personal injury firms plan their intake, staffing, and marketing spend. This piece walks through what SB 623 actually proposes, why it has become such a flashpoint between the plaintiffs' bar and the insurance industry, and what firms should be thinking about regardless of how the bill ultimately fares.

What SB 623 Actually Proposes

At its core, SB 623 targets the gap between what medical providers bill for treatment and what actually gets paid, whether by an insurer, a health plan, or a letter of protection arrangement with a treating provider. Under the current framework that many California plaintiffs' attorneys rely on, a jury can often be shown the full billed amount for medical treatment, even when the provider ultimately accepted a substantially lower negotiated payment. Proponents of SB 623 argue this creates an inflated picture of true economic loss, particularly in cases where treatment was arranged through litigation-focused medical funding rather than a client's own health insurance. The bill's supporters have pointed to reference pricing tools, including data sources like FAIR Health, as a more defensible way to establish what medical treatment reasonably costs in a given geographic market, rather than relying on billed charges that may not reflect what anyone actually paid.

The bill has moved through California's legislative process in stages typical of contested tort-adjacent legislation, with committee hearings drawing testimony from both insurance industry representatives and plaintiffs' attorneys, and amendments introduced along the way as lawmakers attempt to balance competing interests. Attorneys tracking the bill closely have noted that its exact scope, which providers and treatment types would be affected, how the reasonable-value standard would actually be calculated and applied at trial, and what transition rules would govern cases already in progress, has shifted somewhat as the bill moves through committee. This makes it important for firms to track the current, active version of the bill rather than relying on early summaries that may no longer accurately describe its provisions.

Why the Insurance Industry Is Pushing This Bill

It's not a coincidence that insurance trade groups have been among the most vocal supporters of medical bill caps in California and in similar legislative efforts in other states. Insurers have long argued that billed medical charges, especially those generated through arrangements where a provider treats a plaintiff on a lien or letter of protection basis with no upfront payment, do not reflect the actual cost of care and inflate settlement demands and jury awards well beyond what insurers view as fair value. From the insurance industry's perspective, tying admissible medical expenses to a more standardized reasonable-value benchmark reduces unpredictability in claims reserves and, over time, could meaningfully reduce the average payout on litigated and settled personal injury claims across the state.

Insurance industry advocacy around bills like SB 623 typically frames the issue in terms of affordability, arguing that inflated medical damages contribute to rising auto and general liability insurance premiums for California consumers and businesses. Whether that framing accurately reflects the underlying cost drivers of insurance premiums is a genuinely contested empirical question, and plaintiffs' attorneys have pushed back on the idea that medical bill presentation rules are a meaningful driver of broader insurance costs. Regardless of which side has the stronger argument, the affordability narrative has proven to be a durable and politically effective one for insurance-backed advocacy campaigns in state legislatures across the country.

How This Could Affect Case Valuation

Medical specials have never been the only factor in valuing a personal injury case, but they have functioned as an important reference point, particularly in negotiations where an adjuster or defense attorney is trying to benchmark a reasonable settlement range against comparable claims. If admissible medical expenses shrink under a bill like SB 623, the immediate concern among plaintiffs' attorneys is that economic damages calculations could shrink correspondingly, and because some multiplier-based approaches to estimating non-economic damages have historically referenced the economic damages figure as a loose starting point, a reduction in provable medical specials could indirectly pressure non-economic damages valuations as well, even though the two categories are legally distinct and are not supposed to move in lockstep.

It's worth noting that the practical size of this effect would likely vary considerably by case type and by how a given plaintiff's treatment was originally financed. A client who received all treatment through employer-sponsored health insurance, with modest out-of-pocket costs, might see relatively little change in provable specials under a reasonable-value standard, since insurance-negotiated rates already function as a rough proxy for the kind of reasonable-value benchmark the bill contemplates. A client who received treatment entirely through letter of protection arrangements with no insurance involved at all would likely see a more significant shift, since the full billed amount in that scenario has historically been the only figure available to present as the medical specials baseline.

• Billed charges versus paid amounts becomes the central evidentiary fight in medical damages presentation.
• Reference pricing tools like FAIR Health data could become standard exhibits in both settlement negotiations and trial.
• Letter of protection and lien-based treatment arrangements face heightened scrutiny under a reasonable-value standard.
• Adjusters may recalibrate internal settlement authority ranges well before any bill formally takes effect.
• Firms that rely heavily on aggressive billed-charge presentations may need to rebuild parts of their case-building playbook.

The Counterargument From the Plaintiffs' Bar

Trial lawyer associations and consumer advocacy groups opposing SB 623 have raised a different set of concerns, chief among them that reference pricing databases do not always account for regional variation in the actual cost of care, provider specialization, or the reality that many injured plaintiffs, particularly those without health insurance, have no realistic access to treatment at a hypothetical reduced rate. Critics also argue that letter of protection arrangements exist specifically because injured people without insurance or savings need a way to access necessary treatment before a case resolves, and that capping admissible medical expenses at a rate insurers themselves helped define risks systematically undercompensating exactly the plaintiffs who can least afford it. There is also a broader concern that this kind of legislation, once passed in one state, tends to become a template insurers push in other legislatures.

Opponents have also raised process-oriented objections, arguing that a reasonable-value standard set primarily through reference to insurer-influenced pricing databases effectively lets one side of the litigation help define the evidentiary rules that will later govern how strong its own defense position is. Some critics have proposed alternative approaches, such as requiring disclosure of both billed and paid amounts to the jury rather than excluding billed amounts outright, letting jurors weigh the full picture rather than having a single reference-value figure substituted for actual billing records. Whether any such compromise language survives the legislative process remains an open question as the bill continues moving through committee.

What Happens to Rideshare and Auto Claims Specifically

Auto and rideshare injury claims are likely to feel any change in medical bill admissibility rules more acutely than some other personal injury categories, simply because of volume. California processes an enormous number of motor vehicle injury claims each year, and many of these plaintiffs, particularly rideshare passengers and gig-economy drivers, are underinsured or uninsured and rely on letter of protection treatment to get care started while liability and coverage questions are sorted out. If SB 623 or similar legislation changes how those medical bills get proven, firms handling high volumes of auto and rideshare cases may see a compounding effect: not just a change in individual case value, but a change in the overall economics of handling high-volume, lower-severity claims that have historically been a meaningful part of many PI firms' caseloads.

This dynamic is worth watching alongside separate developments in California's rideshare insurance landscape, including negotiated frameworks and legislative proposals addressing transportation network company coverage minimums. A firm handling a large rideshare caseload could, in theory, face two simultaneous shifts: a change in how medical specials are proven under something like SB 623, and a change in available coverage limits under separate rideshare insurance legislation. Firms with meaningful rideshare and auto accident practice concentration have particular reason to track both threads closely rather than treating them as unrelated developments, since their combined effect on case economics could be more significant than either change considered in isolation.

How Firms Are Preparing Regardless of the Outcome

Whether or not SB 623 passes in its current form, or passes at all, forward-looking firms are already building more defensible documentation practices around medical treatment costs rather than waiting to see how the legislative process shakes out. That means keeping cleaner records of what was actually billed versus what was actually paid or written off, understanding how reference pricing tools work well enough to use them proactively in negotiations rather than being caught off guard by a defense expert relying on one, and having honest conversations with treating providers and funding partners about how billing practices might need to adapt if a reasonable-value standard becomes the norm rather than the exception.

Some firms have started incorporating reference pricing checks into their own case evaluation process even before any bill takes effect, using tools like FAIR Health proactively to sanity-check medical specials before finalizing a demand package, rather than waiting for a defense expert to raise the issue during negotiation. This kind of proactive approach serves two purposes: it reduces the risk of a demand package looking inflated or poorly supported if a defense attorney later introduces reference pricing data unprompted, and it gives attorneys a clearer, more realistic sense of how a case might value under a future reasonable-value standard, which is useful information for setting client expectations early in the representation.

• Track both billed and paid amounts for every significant medical provider on active cases going forward.
• Build familiarity with FAIR Health and comparable reference pricing tools before they show up in a defense expert report.
• Revisit letter of protection relationships to understand how funding partners might adjust if reimbursement caps take effect.
• Model how a meaningful reduction in average medical specials would affect overall case value and firm revenue projections.
• Stay engaged with state trial lawyer associations tracking the bill's progress and any amended versions.

The Bigger Picture for Case Value Legislation

SB 623 is part of a broader pattern of tort reform-adjacent legislation that surfaces periodically in state legislatures, often backed by well-funded insurance industry coalitions and opposed by equally well-organized plaintiffs' bar groups. California's size and influence mean that whatever ultimately happens with this bill, whether it passes, stalls, or gets significantly amended, will likely be studied closely by advocates on both sides in other states considering similar measures. Firms operating in California, and firms watching from other jurisdictions, have real reason to pay attention not just to the immediate financial impact but to the precedent a bill like this could set for how medical damages get proven in personal injury litigation more broadly going forward.

This pattern has played out before with other categories of tort-adjacent reform, where a bill introduced in one state generates years of legislative activity in others as advocacy groups on both sides refine their arguments and adapt to what worked or failed in earlier fights. Attorneys who track SB 623 closely today are, in effect, building an early understanding of an issue they may well need to engage with again in their own state's legislature down the road, even if they don't currently practice in California, simply because medical bill admissibility reform has become a recurring theme in insurance-backed legislative advocacy nationally.

State trial lawyer associations across the country have generally responded to this pattern by building shared resources and coordinating advocacy efforts across state lines, recognizing that a well-funded, well-organized push in one legislature often previews a similar effort elsewhere within a year or two. Firms wanting to stay ahead of this kind of legislative risk, rather than reacting only once a bill has already gained momentum in their own state, benefit from paying attention to how these fights unfold in bellwether states like California even when the immediate legal impact hasn't yet reached their own jurisdiction.

What This Means for Firm Planning

For firm owners thinking beyond the legal mechanics, the practical question is how much operational and marketing planning should shift in anticipation of a bill that hasn't yet become law and could still change substantially before any final vote. Most experienced firm leaders treat this the way they treat any pending legislative risk: they build awareness into their planning without overreacting to a bill that is still moving through committee, they diversify case types and geographic reach where practical so no single legislative change can meaningfully disrupt overall firm revenue, and they keep close communication with referral partners and lead sources who are often tracking the same regulatory landscape from a slightly different angle.

Firms that rely on purchased or referred case volume also have reason to have candid conversations with those partners about how a shift in medical bill admissibility standards might affect the kinds of cases worth prioritizing, since a lead source or referral partner with visibility into evolving case economics across many firms can offer useful, aggregated perspective that a single firm working in isolation might not have access to on its own. This kind of ongoing dialogue is particularly valuable for firms with a heavy concentration in auto and rideshare case types, where the potential impact of medical bill admissibility changes is likely to be felt earliest and most directly.

SB 623 remains a developing story, and its final language, timeline, and eventual fate are not yet settled. What is clear is that California personal injury attorneys have good reason to understand the bill's mechanics now rather than scrambling to adapt after the fact, since even a partial version of the proposed changes could meaningfully affect how medical expenses get proven and how firms value their caseloads going forward. Firms that build flexible documentation and negotiation practices today will be better positioned no matter which direction the legislation ultimately takes.